Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
Follow-Up Questions
Minerva Neurosciences Inc (NERV)'in P/E oranı nedir?
Minerva Neurosciences Inc 'in P/E oranı 10.393 'dir
Minerva Neurosciences Inc 'in CEO'su kimdir?
Dr. Remy Luthringer 2014 'den beri şirketle birlikte olan Minerva Neurosciences Inc 'in Executive Chairman of the Board of Directors 'ıdır.
NERV hissesinin fiyat performansı nasıl?
NERV 'in mevcut fiyatı $2.02 'dir, son işlem günde 1.69% decreased etti.
Minerva Neurosciences Inc için ana iş temaları veya sektörler nelerdir?
Minerva Neurosciences Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 3 analist Minerva Neurosciences Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 0 güçlü al, 0 al, 3 tut, 1 sat ve 0 güçlü sat içermektedir
